𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis

✍ Scribed by G. Kolarz; F. Mayrhofer; P. Peichl; E. Posch; O. Scherak; F. Singer; N. Thumb; A. Wottawa

Publisher
Springer
Year
1995
Tongue
English
Weight
304 KB
Volume
14
Category
Article
ISSN
0770-3198

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Weekly intravenous methotrexate in the t
Weekly intravenous methotrexate in the treatment of rheumatoid arthritis
✍ Dr. Robert M. Michaels; David J. Nashel; Andrea Leonard; Anthony J. Sliwinski; S πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 279 KB πŸ‘ 2 views

Patients with rheumatoid arthritis who are unresponsive to antiinflammatory drugs and slow-acting agents such as gold, hydroxychloroquine, and Dpenicillamine, pose a therapeutic challenge. This report details the effectiveness of weekly intravenous methotrexate in 14 such patients resistant to stand

Methotrexate in rheumatoid arthritis. To
Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment
✍ Graciela S. AlarcΓ³an; Irene C. Tracy; Warren D. Blackburn Jr. πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 543 KB

In an effort to understand the prognostic features that may influence the probability of a patient's continuing to take methotrexate (MTX) over time, we studied 152 rheumatoid arthritis patients treated with MTX between 1981 and 1986. The overall probability of continuing to take MTX was 71.2% at 1